Moderna (MRNA) traded lower (down roughly 3%) as investors continued to price in the fallout from a pivotal Phase 3 miss for its cytomegalovirus (CMV) vaccine, mRNA-1647. The program’s efficacy range came in well below expectations, and Moderna halted development, removing a potential future growth driver and reinforcing concerns about pipeline conversion risk after COVID-era revenues faded. (tradingview.com)

CMV prevention has been viewed as an important non-COVID vaccine opportunity, and a late-stage failure typically forces investors to recalibrate both probability of success and the timing of future revenue from the infectious-disease pipeline. With mRNA-1647 discontinued, the market focus shifts to whether Moderna can replace that lost optionality with nearer-term programs (such as combination respiratory vaccines) and whether it can maintain investor confidence while it funds a broad development portfolio. (modernatx.com)

The selling pressure has been occurring against a backdrop of increased regulatory uncertainty for Moderna’s vaccine franchise. In February 2026, the FDA issued a refusal-to-file decision for Moderna’s seasonal flu vaccine application, leaving U.S. timing unclear and raising questions about trial design expectations for older adults—an added overhang that can magnify downside reactions on any negative pipeline news. (apnews.com)

Investors will likely focus on how Moderna reallocates resources after the CMV discontinuation, whether it can de-risk key respiratory and oncology programs with clean data, and any path to resolving the flu filing issue. Near-term catalysts include updates on ongoing late-stage studies and clearer timelines around regulatory interactions, which could either stabilize sentiment or extend volatility if additional delays emerge. (modernatx.com)